Biohaven Ltd. (BHVN): Capital Expenditures
$715.0K
Year ended 2025-12-31
$475.0K
Trailing 12 months to 2026-06-30
-51.0%
3-year compound annual growth
-8.2%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $715.0K | -82.3% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $4.05M | +32.8% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $3.05M | -49.8% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $6.07M | +547.5% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $938.0K | -14.5% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $1.10M | n/a | 2023-03-23, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Biohaven Ltd. (BHVN) | 2025-12-31 | $715.0K | -82.3% |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | 2025-12-31 | $606.0K | n/m |
| BGM Group Ltd. (BGM) | 2025-09-30 | $1.57M | +552.4% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $686.0K | +379.7% |
| Bicara Therapeutics Inc. (BCAX) | 2025-12-31 | $280.0K | +294.4% |
| Enliven Therapeutics, Inc. (ELVN) | 2025-12-31 | $158.0K | +259.1% |
| MapLight Therapeutics, Inc. (MPLT) | 2025-12-31 | $473.0K | -38.6% |
| MoonLake Immunotherapeutics (MLTX) | 2025-12-31 | $35.0K | -93.3% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $953.0K | n/a |
Compare BHVN, BBOT, BGM, ARQT side by side · Screen every company in Pharmaceutical Preparations ↗